SLAT Regulates CD8\(^+\) T Cell Clonal Expansion in a Cdc42- and NFAT1-Dependent Manner

Sonia Feau, Stephen P. Schoenberger, Amnon Altman and Stéphane Bécart

*J Immunol* 2013; 190:174-183; Prepublished online 28 November 2012;
doi: 10.4049/jimmunol.1201685
http://www.jimmunol.org/content/190/1/174
SLAT Regulates CD8+ T Cell Clonal Expansion in a Cdc42- and NFAT1-Dependent Manner

Sonia Feau,* Stephen P. Schoenberger,* Amnon Altman,†,1 and Stéphane Bécourt†,1

After antigenic stimulation, CD8+ T cells undergo clonal expansion and differentiation into CTLs that can mount a strong defense against intracellular pathogens and tumors. SWAP-70–like adapter of T cells (SLAT), also known as Def6, is a novel guanine nucleotide exchange factor for the Cdc42 GTPase and plays a role in CD4+ T cell activation and Th cell differentiation by controlling Ca2+/NFAT signaling, but its requirement in CD8+ T cell response has not been explored. Using a range of transgenic and knockout in vivo systems, we show that SLAT is required for efficient expansion of CD8+ T cells during the primary response but is not necessary for CTL differentiation. The reduced clonal expansion observed in the absence of SLAT resulted from a CD8+ T cell–intrinsic proliferation defect and a reduced IL-2–dependent cell survival. On a molecular level, we show that Def6 deficiency resulted in defective TCR/CD28-induced NFAT translocation to the nucleus in CD8+ T cells. Constitutively active Cdc42 or NFAT1 mutants fully restored the impaired expansion of Def6−/− CD8+ T cells. Taken together, these data describe a new and pivotal role of SLAT-mediated NFAT activation in CD8+ T cells, providing new insight into the signaling pathways involved in CD8+ T cell proliferation. The Journal of Immunology, 2013, 190: 174–183.

A functional CD8+ T cell response is critical for host defense against intracellular pathogens and malignancies. Upon recognition of cognate Ag, naive CD8+ T cells undergo a vigorous Ag-specific clonal expansion and differentiation into effector CD8+ CTLs, producing cytokines (mainly IFN-γ and TNF-α) and cytotoxic effector molecules (such as perforin and granzyme B) to mediate direct killing of target cells. Once an infection has been successfully cleared, the CTLs undergo a rapid contraction phase characterized by extensive cell death of the majority (>90%), leaving behind a stable pool of long-lived memory cells that provide long-term immunity against subsequent infections via rapid reactivation (1). It has been shown that extracellular stimuli such as Ag, costimulatory molecules (2, 3), and cytokines (4, 5) instruct naive CD8+ T cells for clonal expansion and memory formation. The integration of these instruction signals triggers downstream intracellular signaling pathways leading to specific transcriptional programs that govern the fate of CD8+ T cells (i.e., activation, proliferation, survival, differentiation). This research area remains intensively studied and is crucial for the design of novel vaccines against malignancies and pathogen infections.

SWAP-70–like adapter of T cells (SLAT; also known as IBP or Def6), which is encoded by the Def6 gene, has been recently identified as a novel TCR-regulated guanine nucleotide exchange factor (GEF) for Cdc42 (and to a lesser extent Rac1) (6–8). SLAT is abundantly expressed in central and peripheral lymphoid tissues, with high levels found in thymocytes and peripheral T cells (7, 9, 10). Our previous examination of Def6-deficient (Def6−/−) mice revealed SLAT to be a critical selective regulator of the TCR-coupled Ca2+/NFAT signaling pathway (10), controlling positively CD4+ Th cell activation and differentiation, as evidenced by its critical role in the development of T cell–dependent inflammatory diseases such as asthma (10) or experimental autoimmune encephalomyelitis (11). Moreover, the Ca2+/NFAT regulatory activity of SLAT depends on actin polymerization and functional Cdc42 activity (6). Although the function of NFAT in CD4+ T cell activation and differentiation is well established, its role in CD8+ T cells is less clearly defined. Although NFAT transcriptional activity seems to be limited in Ag-stimulated CD8+ T cells by comparison with CD4+ T cells (12), NFAT1 has been shown to translocate to the nucleus of CD8+ T cells upon TCR stimulation and to regulate IFN-γ gene expression (13). In addition, NFAT1 and its Ca2+/calmodulin-dependent phosphatase, calcineurin, have been implicated in peripheral CD8 tolerance in vivo (14). Finally, silencing of cytokine production by CD8+ T cells during chronic viral infections, such as murine lymphocytic choriomeningitis virus and human HIV, has been causally linked to impaired NFAT nuclear translocation (15).

In this study, we examined the involvement of SLAT in CD8+ T cell activation and differentiation in vivo. We found that SLAT was required for the expansion of Ag-specific CD8+ T cells during the primary response by intrinsically promoting their proliferation and by regulating the rate of CD8+ T cell survival in an IL-2–dependent manner. In contrast, SLAT was not critical for CD8+ T cell effector functions, such as cytokine production, degranulation, and cytolytic activity. Furthermore, constitutively active Cdc42 or NFAT1 mutants restored the proliferation of Def6−/− CD8+ T cells in vivo. These data highlight a new role of SLAT and
its proximal (Cdc42) and distal (NFAT) effectors in CD8+ T cell biology. Thus, SLAT may represent a novel target for manipulating CD8+ T cell expansion in vaccination and other immunotherapies.

Materials and Methods

Mice

Mice were maintained under specific pathogen-free conditions in accordance with guidelines of the Association for Assessment and Accreditation of Laboratory Animal Care International. The studies described in this article conform to the principles outlined by the Animal Welfare Act and the National Institutes of Health guidelines for the care and use of animals in biomedical research. C57BL/6 (B6; CD45.2+), B6.SJL (CD45.1+), and Rag2−/− mice were purchased from The Jackson Laboratory. B6 (CD45.1+ 2+) mice were generated by crossing B6 (CD45.2+) with B6.SJL (CD45.1+) mice. Def6−/− mice on a B6 background (10), OVA-specific OT-1 TCR-transgenic (Tg) CD45.1+ and Act-mOVA/Kb+/- mice on a B6 background (16) have been previously described. Def6−/− OT-1 TCR-Tg CD45.2+ mice were generated by crossing Def6−/− mice with OT-1 TCR-Tg CD45.2+ mice, and their T cells were used as a source of Vβ5+Vα2 CD8+ T cells specific for amino acid residues 257–264 of OVA (OVA257–264; SIINFEKL peptide). Six- to twelve-week-old mice were used in all experiments.

Immunizations and adoptive transfers

Groups of mice were primed either with 5 × 10^6 Act-mOVA/Kb+/- splenocytes i.v. or with 3000 CFU OVA-expressing Listeria monocytogenes (Lm-OVA) i.v. The mice were challenged 7 d later with 1 × 10^6 ActA-deficient (ActA−) Lm-OVA i.v. For adoptive cotransfer, Def6−/− (CD45.2) and wild-type (WT; CD45.1) OT-1 TCR-Tg mice were bled, and the number of OT-I cells was determined by counting and FACs staining for Vα2+Vβ5+ cells. Fifty of each Def6−/− and WT OT-I CD8+ T cells were injected i.p. per mouse into naive recipient mice 1 d prior to immunization.

Tetramer staining

Cells were stained for 10 min at room temperature with PE-conjugated OVA257–264–H2-Kk tetramer (BD Pharmingen), followed by staining with anti-CD8 (PE-TR), anti-CD62L (Alexa Fluor 750), anti-CD44 (Alexa Fluor 700), and anti-CD127 (allophycocyanin), and anti–KLRG-1 (PE–Cy7) Abs. The Abs were purchased from BD Pharmingen, eBioscience, or BioLegend. Samples were acquired and analyzed as described earlier.

CD107a staining

Splenocytes (1 × 10^6 to 2 × 10^6) from immunized mice were plated in 96-well round-bottom plates in 200 μl of culture medium plus OVA257–264 peptide (1 μg/ml) in the presence of GolgiPlug, GolgiStop (BD Biosciences), and CD107a Ab for 5 h at 37°C. Cells were stained with anti-CD8 (PE-TR), CD44 (Alexa Fluor 700), CD45.1 (Pacific blue), and CD45.2 (PerCP–Cy5.5) followed by fixation with Cytofix/Cytoperm (BD Biosciences) for 20 min at 4°C. Fixed cells were subjected to intracellular staining in Perm/Wash buffer (BD Biosciences) for 30 min at 4°C with anti–CD45.2 (PerCP–Cy5.5) followed by Cytofix/Cytoperm (BD Biosciences) for 20 min at 4°C. Fixed cells were subjected to intracellular staining in Perm/Wash buffer (BD Biosciences) for 30 min at 4°C with anti-CD107a Abs. The cells were harvested. Samples were acquired on an LSR II flow cytometer (Becton Dickinson), and data were analyzed with FlowJo software.

Ex vivo cytotoxicity assay

Def6−/− or WT OT-I mice were immunized i.v. with 5 × 10^6 Act-mOVA splenocytes. Activated (CD44hi/CD8+Vβ5+3) OT-I CD8+ splenocytes were sorted 7 d later. Different numbers of effector cells were seeded in quadruplicate in 96-well round-bottom plates in the presence of 1 × 10^5 OVA-expressing EL4 (mOVA-EL4) target cells, which were previously labeled with 6 μM 5-Iodotryptophan (5-IOT). The effector–target ratio was determined by adding medium instead of effector cells. After overnight culture, cells were collected on glass-fiber filters and, the 5-IOT label retained in live target cells was measured in a gamma counter.

In vivo cytotoxicity assay

Cytotoxicity assays were performed by evaluating immune intact or adoptively transferred mice. For intact mouse immunization, mice were primed with Act-mOVA/Kb+/- splenocytes as described earlier. In the adoptive transfer system, B6 (CD45.2+) mice were injected i.v. with 5 × 10^6 Act-mOVA/Kb+/- splenocytes. Six days after immunization of intact mice or 5 d after immunization of adoptive transfer recipients, the mice received i.v. 5 × 10^3 B6.SJL (CD45.1+) splenocytes, which were stained with 0.2 μM CFSE (CFSEdil) and loaded with the specific peptide (OVA257–264) as a source of Ag-specific target cells. As a control, the mice also simultaneously received a similar number of splenocytes labeled with 0.2 μM CFSE (CFSEdil) and loaded with an irrelevant peptide (Ski9 peptide, E1B192–200). Spleen cell suspensions were prepared 15 h later, and samples were acquired and analyzed as described earlier. Percent specific killing was calculated by the following formula: 100 − [(% CFSEdil% CFSElow in primed condition)/(% CFSEdil% CFSElow in naive condition)].

Generation of retrogenic mice

The empty RV-IRES-GFP retroviral vector and a retroviral vector expressing a constitutively active Cdc42 (Cdc42CA) mutant (pMX GFP) (PMX GFP Cdc42Q61L) have been described (18). The retroviral vector expressing a constitutively active form of Nfat1 containing two additional point mutations, which abolish NFAT homodimerization but not NFAT:AP-1 heterodimerization and, hence, leading to productive T cell activation (RV-CA-NFAT1-DCC9–QQEE or “NFATCA9DCC9” mutant) (18), was kindly provided by Dr. F. Macian (18). Plat-E packaging cells (19) (0.5 × 10^5 cells in 2 ml DMEM plus 10% FBS) were plated in a 6-well plate. After overnight incubation, the cells were transfected with 3 μg retroviral plasmid DNA with TransIT-LTI transfection reagent. After 24 h, the medium was replaced with complete DMEM containing 10% FBS. Cultures were maintained for 24 h, and the retroviral supernatant was harvested, filtered through 0.45-μm filters, and used for infection.

Bone marrow (BM) cells were harvested from the femurs of Def6−/− or OT-I TCR-Tg CD45.2+ or OT-I TCR-Tg CD45.1+ mice. Lin− cells were isolated by negative selection using a lineage cell depletion kit (MACS) and cultured in complete DMEM containing 20% FCS supplemented with IL-3 (10 ng/ml), IL-6 (20 ng/ml), and stem cell factor (50 ng/ml). After
24 h, the cells were resuspended in 0.5 ml complete DMEM and were added to 0.5 ml retroviral supernatant, supplemented with polybrene (5 μg/ml final concentration) and recombinant cytokines (IL-3, IL-6, and stem cell factor), and centrifuged at 2000 rpm for 1 h at room temperature. Cells were then incubated for 6 h at 32°C and cultured overnight at 37°C, followed by two additional retroviral infections at daily intervals. Transduced (GFP<sup>+</sup>) progenitor cells were sorted and injected (2 × 10<sup>6</sup> cells) i.v. into sublethally irradiated (450 rad) recipient <i>Rag1</i><sup>−/−</sup> B6 mice. Mice were analyzed 8 wk later for engraftment by analyzing their PBLs for OVA<sub>257-264</sub>-specific CD8<sup>+</sup> T cells.

**Subcellular fractionation and immunoblotting**

Purified CD8<sup>+</sup> T cells (1 × 10<sup>6</sup>) were washed with ice-cold PBS and resuspended in 100 μl buffer A (10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 1 mM DTT, and proteases inhibitors) for 15 min on ice. Nonidet P-40 was then added to a final concentration of 0.5%; samples were quickly vortexed for 10 s and centrifuged for 2 min (14,000 × g at 4°C). The supernatant was collected as the cytosolic fraction. Nuclear pellets were washed twice with buffer A lacking Nonidet P-40, resuspended in 40 μl buffer B (20 mM HEPES, pH 7.9, 400 mM NaCl, 1 mM EDTA, 1 mM DTT, and proteases inhibitors), vortexed for 10 s, and rocked for 30 min at 4°C. Samples were centrifuged for 10 min at 14,000 × g, and the supernatant was collected as the nuclear fraction. Samples were resolved by SDS-PAGE, transferred to nitrocellulose membrane, and immunoblotted with Abs against hemagglutinin, lamin B, NFAT1 (4G6-G5) (both from Santa Cruz Biotechnology), β-actin (BioLegend), or rat α-tubulin (YLI1/2, Serotec). Signals were detected using the ECL system (Amersham Biosciences).

**Reporter assays**

SV40 large T Ag-transfected human leukemic Jurkat T cells (Jurkat-Tag) were transfected with NFAT-luciferase plasmids plus a β-galactosidase (β-Gal) reporter plasmid as described (20). Transfected cells were cultured overnight, lysed, and luciferase or β-Gal activities were determined as described (20). The results are expressed in arbitrary luciferase units normalized to β-Gal activity in the same cells.

**Statistical analysis**

Data were analyzed using PRISM software (GraphPad, San Diego, CA). Differences between groups were examined for statistical significance using an unpaired two-tailed Student t test. Unless otherwise indicated, data represent the mean ± SEM, with p < 0.05 considered statistically significant.

**Results**

**SLAT is critical for Ag-specific CD8<sup>+</sup> T cell primary expansion**

Although SLAT is required for CD4<sup>+</sup> T cell activation and differentiation (6, 10, 11, 21), its role in CD8<sup>+</sup> T cells has not been addressed. To assess directly the in vivo requirement of SLAT in CD8<sup>+</sup> T cell responses, we immunized WT or <i>Def6</i><sup>−/−</sup> mice with a nonreplicating, noninflammatory, cell-based immunogen (i.e., splenocytes from Act-mOVA mice), which expresses OVA under control of the actin promoter and has a homozygous deletion of the gene encoding H-2K<sup>b</sup> (Act-mOVA/K<sup>b</sup>−/−). These splenocytes cannot directly present the OVA Ag, leading to its cross-priming in the context of H-2K<sup>b</sup> (24). We adoptively transferred equal numbers of naive (CD62<sup>Lhigh</sup>CD44<sup>+</sup>WT CD45.1<sup>+</sup> and <i>Def6</i><sup>−/−</sup>/CD45.2<sup>+</sup>OT-I CD8<sup>+</sup> T cells into WT CD45.1<sup>−/−</sup> recipient mice. Of note, we transferred a very small number of cells (50 each) to most closely mimic the endogenous CD8<sup>+</sup> T cell response without suppressing it (17, 25) (as shown in Fig. 3A, right column). The next day, we immunized the recipient mice with Act-mOVA/K<sup>b</sup>−/− splenocytes and evaluated the expansion of WT and <i>Def6</i><sup>−/−</sup> CD8<sup>+</sup> T cells, which were identified based on their distinct CD45 congenic markers, at the peak of the response (day 7). We observed a substantial clonal expansion of donor WT OT-I cells in the blood (Fig. 3A) and spleen (Fig. 3C) as evidenced by frequency and absolute number of the recipient mice. By contrast, the expansion of <i>Def6</i><sup>−/−</sup> OT-I T cells was significantly diminished (Fig. 3A, 3C). Calculation of the ratio of WT to <i>Def6</i><sup>−/−</sup> OT-I cells in the recipient mice showed that WT CD8<sup>+</sup> cells expanded on average ~2.5 times more than the <i>Def6</i><sup>−/−</sup> cells (Fig. 3B). However, the expanded <i>Def6</i><sup>−/−</sup> OT-I cells displayed a frequency of SLECs and MPECs similar to that of WT OT-I cells (Fig. 3E) and a only small decrease in T-bet and Eomes expression (Fig. 3D) and in IFN-γ/TNF-α-producing cells (Fig. 3F) compared with WT cells. Furthermore, <i>Def6</i><sup>−/−</sup> and WT donor OT-I T cells displayed similar cytolytic activity in vivo and ex vivo (Supplemental Figs. 1A and 1B, respectively) and CD8<sup>+</sup> T cell degranulation determined by cell surface modulation of CD107a/LAMP-1 upon Ag encounter (Supplemental Fig. 1C).

**Intrinsic effects of Def6 deficiency on CD8<sup>+</sup> T cell expansion**

The defect in <i>Def6</i><sup>−/−</sup> CD8<sup>+</sup> T cell priming could reflect defective activation of CD4<sup>+</sup> T cells or impaired function of Ag-presenting dendritic cells (DCs), which also express SLAT. Therefore, we wanted to determine whether the observed defect is CD8<sup>+</sup> T cell–intrinsic. To this end, we crossed <i>Def6</i><sup>−/−</sup> mice onto an OT-I background, in which the majority of CD8<sup>+</sup> T cells express a Vα2Vβ5 TCR recognizing the OVA<sub>257-264</sub> peptide presented in the context of H-2K<sup>b</sup> (24). We adoptively transferred equal numbers of naive (CD62<sup>Lhigh</sup>CD44<sup>+</sup>WT CD45.1<sup>−/−</sup> and <i>Def6</i><sup>−/−</sup>/CD45.2<sup>+</sup>OT-I CD8<sup>+</sup> T cells into WT CD45.1<sup>−/−</sup> recipient mice. Of note, we transferred a very small number of cells (50 each) to most closely mimic the endogenous CD8<sup>+</sup> T cell response without suppressing it (17, 25) (as shown in Fig. 3A, right column). The next day, we immunized the recipient mice with Act-mOVA/K<sup>b</sup>−/− splenocytes and evaluated the expansion of WT and <i>Def6</i><sup>−/−</sup> CD8<sup>+</sup> T cells, which were identified based on their distinct CD45 congenic markers, at the peak of the response (day 7). We observed a substantial clonal expansion of donor WT OT-I cells in the blood (Fig. 3A) and spleen (Fig. 3C) as evidenced by frequency and absolute number of the recipient mice. By contrast, the expansion of <i>Def6</i><sup>−/−</sup> OT-I T cells was significantly diminished (Fig. 3A, 3C). Calculation of the ratio of WT to <i>Def6</i><sup>−/−</sup> OT-I cells in the recipient mice showed that WT CD8<sup>+</sup> cells expanded on average ~2.5 times more than the <i>Def6</i><sup>−/−</sup> cells (Fig. 3B). However, the expanded <i>Def6</i><sup>−/−</sup> OT-I cells displayed a frequency of SLECs and MPECs similar to that of WT OT-I cells (Fig. 3E) and a only small decrease in T-bet and Eomes expression (Fig. 3D) and in IFN-γ/TNF-α-producing cells (Fig. 3F) compared with WT cells. Furthermore, <i>Def6</i><sup>−/−</sup> and WT donor OT-I T cells displayed similar cytolytic activity in vivo and ex vivo (Supplemental Figs. 1A and 1B, respectively) and CD8<sup>+</sup> T cell degranulation determined by cell surface modulation of CD107a/LAMP-1 upon Ag encounter (Supplemental Fig. 1C). Overall, these results recapitulate the data obtained in intact immunized
mice (Figs. 1, 2) and, moreover, clearly indicate that the defect in the priming and expansion of Ag-specific T cells observed in Def6−/− mice is CD8+ T cell–intrinsic.

The cross-priming model using Act-mOVA/Kb−/− splenocytes as immunogens has been shown to result in accelerated acquisition of memory phenotype and function, and effector CD8+ T cells cross-primed under these conditions respond vigorously to short-interval reexposure to Ag (26). This accelerated memory development is evident from the prevalence of MPECs over SLEC (Fig. 3H). As in the case of CD8+ T cells from Act-mOVA/Kb−/− splenocyte–primed mice (Supplemental Fig. 2A–C), Def6−/− T cells also displayed an impaired secondary T cell expansion after ActA− Lm-OVA rechallenge at day 54 (Supplemental Fig. 3).

Impaired proliferation and enhanced death of Def6−/− CD8+ T cells

To investigate further the cause of the reduced expansion of Def6−/− CD8+ T cells, we first evaluated their proliferative capacities in vivo. We transferred CFSE-labeled WT or Def6−/− CD45.2+ OT-I CD8+ T cells into WT B6.SJL (CD45.1+) mice, immunized the recipients with Act-mOVA/Kb−/− splenocytes, and analyzed the accumulation of the donor cells and their division profile by CFSE dilution in recipient spleens. Def6−/− CD8+ T cells exhibited impaired accumulation compared with WT cells, reflecting a significantly lower number of cycling cells (Fig. 4A). Analysis of cell number recovered at each division cycle showed that Def6−/− CD8+ T cells divided at a rate similar to that of WT cells in response to OVA priming during the first two cycles but displayed a reduced rate at subsequent division cycles (Fig. 4B).
reduced proliferation in response to anti-CD3/CD28 stimulation was confirmed by measuring [3H]thymidine incorporation (Supplemental Fig. 4A). With regard to cell survival, we could not assess the proportion of dying cells in vivo, presumably due to the rapid engulfment of apoptotic cells by phagocytes. However, we determined the frequency of dividing versus dying CD8+ T cells in vitro by CFSE labeling and concurrent staining with active caspase-3 and annexin V mAbs, respectively. We confirmed that Def6−/− CD8+ T cells divide at a slower rate than WT cells in response to anti-CD3/CD28 stimulation (Fig. 4C, 4D). This proliferative defect was accompanied by a 2-fold reduction in the proportion of surviving Def6−/− CD8+ T cells compared with WT cells at all time points assayed (Fig. 4C, 4E). Consistent with their reduced proliferation along with enhanced cell death, anti-CD3/CD28–stimulated Def6−/− CD8+ T cells displayed a drastic decrease in IL-2 production (Supplemental Fig. 4B), although CD3/CD28 engagement induced intact upregulation of CD25 and the activation marker CD69 in Def6−/− CD8+ T cells (Supplemental Fig. 4C). Because IL-2 has been shown to be required for survival (but not for the initiation of CD8 T cell cycling) to sustain CD8 T cell primary expansion (27), we assessed whether addition of exogenous IL-2 could rescue the survival and/or the proliferative defect of Def6−/− CD8+ T cells. Addition of IL-2 restored Def6−/− CD8+ T cell survival at all times assayed (Fig. 4C, 4E) but did not rescue the proliferative defect (Fig. 4C, 4D), indicating that the impaired proliferation of Def6−/− CD8+ T cells reflects a cell-intrinsic defect, whereas the in vitro survival defect was a consequence of diminished IL-2 production. These data collectively suggest that in the absence of SLAT, CD8+ T cell cycling is intrinsically reduced and IL-2–dependent survival is decreased, with both of these effects combining to result in a drastic defect in primary CD8+ T cell expansion.

Dependence of Ag-specific CD8+ T cell expansion on SLAT-mediated Cdc42 and NFAT1 activation

Next, we investigated the molecular mechanism underlying SLAT-mediated Cdc42 and NFAT1 activation by guest on April 12, 2017

Downloaded from http://www.jimmunol.org/ by guest on April 12, 2017

CD8+ T CELL EXPANSION REQUIRES SLAT

FIGURE 2. SLAT is not required for CD8+ T cell differentiation into primary effector CTLs. Mice were primed with 5 × 106 Act-mOVA/Kb−/− splenocytes. On day 7, OVA257–264/Kb-specific CD8+ T cells were stained with H-2Kb–OVA tetramer, and IFN-γ– and TNF-α–producing CD8+ T cells were assessed by ICS after restimulation with OVA peptide for 5 h. (A) Expression of T-bet and Eomes within the OVA257–264/Kb-specific CD8+ T cell population. (B) Expression of KLRG1 and CD127 on OVA−/−–specific CD8+ T cells. KLRG-1highCD127−/− CD8+ T cells are referred to as SLECs, whereas KLRG-1−/−CD127+/+ CD8+ T cells are referred to as MPECs. (C) Frequency of IFN-γ– and TNF-α–producing CD8+ T cells within the IFN-γ+ CD8+ T cells. Each graph represents the mean of six mice/group and is representative of at least two independent experiments. (D) In vivo cytolytic activity of Ag-specific CD8+ T cells from WT versus knockout (KO) mice 6 d after priming with Act-mOVA/Kb−/− splenocytes. Data are presented as the frequency of tetramer+ cells (numbers above outlined areas in first and third panels from left) and killing of target cells pulsed with OVA257–264 peptide and loaded with a high concentration of the cytosolic dye CFSE (OVA) versus control target cells pulsed with an irrelevant peptide and loaded with a low concentration of CFSE (Sk9) (second and fourth panels from left). Cytotoxicity was determined 16 h after adoptive transfer of target cells. Numbers in plots indicate percentage ± SEM of specific killing of CFSE−/−, OVA-loaded cells. Data are representative of five independent experiments.
CD8+ T cells (Fig. 5A), indicating that SLAT is required for NFAT1 activation in naive CD8+ T cells as well. This result prompted us further to assess whether constitutively active forms of Cdc42 or NFAT1 can restore the impaired expansion of Def6−/− CD8+ T cells in vivo. For this purpose, we used a retrovirus-mediated stem cell gene transfer to generate retrogenic BM chimeric mice, which served as a source of naive CD8+ T cell expressing constitutively active Cdc42 (Cdc42CA) or NFAT1 (NFAT1CA) (Fig. 5B). In the case of NFAT, we used an active mutant that contains two additional point mutations, which preclude NFAT homodimerization (the anergy-inducing form of NFAT, termed hereafter “NFAT1CA dimer”) (18). This mutant was able constitutively to transactivate an endogenous NFAT reporter gene in unstimulated T cells (Supplemental Fig. 2G). Sorted GFP+ (transduced) BM stem cells, isolated as Lin− (Supplemental Fig. 2G), were transferred into sublethally irradiated WT CD45.1/2+ recipients, thus allowing the development of donor-derived T lymphocytes in vivo (30). Six to eight weeks after BM transfer, naive (CD62LhighCD44low) peripheral blood OT-I CD8+ T cells were sorted, and a 1:1 mixture of 50 each of mock-transduced WT cells and Def6−/− CD45.2+ cells transduced with either Cdc42CA or NFAT1CA dimer were adoptively transferred into WT CD45.1/2+ recipient mice (Fig. 5B). Seven days after challenge with Act-mOVA splenocytes, we found that the defective Def6−/− CD8+ T cell primary expansion was restored when the cells were transduced with Cdc42CA as well as with NFAT1CA dimer (Fig. 5C, 5D). Likewise, when rechallenged with Lm-OVA, the Def6−/− OT-I CD8+ T cells expressing Cdc42CA or NFAT1CA dimer, but not the mock-transduced Def6−/− cells, displayed secondary expansion very similar to that of the control, mock-transduced WT cells (Supplemental Fig. 2H, 2I). Together, these findings suggest that defective NFAT signaling, which depends on SLAT-mediated Cdc42 activation, is the cause of the impaired Ag-specific CD8+ T cell expansion.

**Discussion**

In this study, we investigated the impact of Def6 deficiency on different phases of Ag-specific CD8+ T cell responses (i.e., activation, expansion, effector function, and memory development). We report that SLAT is a critical CD8+ T cell–intrinsic positive regulator of T cell expansion but is not required for CD8+ T cell differentiation into effector or memory cells. Moreover, we provide evidence that the reduced Ag-induced expansion of CD8+ T cells in the absence of SLAT results primarily from a T cell–intrinsic defective activation and proliferation of clonal precursors, inducing consequently impaired IL-2–dependent cell survival. Lastly, our finding that the expression of constitutively active mutants of Cdc42 or NFAT1 in naive CD8+ T cells rescued the defective Ag-specific CD8+ T cell response suggests that SLAT controls CD8+ T cell expansion through a Cdc42/NFAT pathway.

The CD8+ T cell expansion defect was observed both in a polyclonal environment (i.e., in intact immunized mice) and in a TCR-Tg adoptive transfer system. The results of the adoptive transfer experiments provide evidence that the expansion defect is intrinsic to the Ag-specific CD8+ T cells, although it does not exclude potential contribution by other cell types that also express SLAT such as DCs or CD4+ T cells, which are well known to play...
CD8+ T cell expansion requires SLAT

A critical role in the generation of an optimal CD8+ T cell response. However, we have previously shown that Def6−/− DCs did not display any defect in Ag presentation to CD4+ T cells (11).

The proliferation of naive CD8+ T cells during a primary response follows a two-phase pattern. The first phase, occurring in the secondary lymphoid organs (SLOs), reflects an initial IL-2–independent expansion of Ag-specific T cells after interaction with APCs. The second phase, which correlates with emigration of the activated CD8+ T cells to peripheral, nonlymphoid target tissues, is associated with the acquisition of effector functions and CD8+ T cell survival, associated with the latter stage of the proliferative phase, were not altered in the absence of SLAT. Finally, the impaired proliferation observed in response to anti-CD3/CD28 stimulation was not rescued by addition of exogenous IL-2.

In CD4+ T cells, SLAT has previously been shown to play a key role in TCR-mediated activation and Ag-specific immunological synapse (IS) formation and stabilization at the T cell–APC interface via its actin regulatory function, a process that is critical for optimal T cell activation in SLOs (6, 33). Furthermore, we found that the expression of constitutively active Cdc42, a target of SLAT, rescued the defective expansion of Def6−/− CD8+ T cells, demonstrating, for the first time to our knowledge, a role of SLAT and its effector Cdc42 in CD8+ T cell expansion in vivo. On the basis of these observations, and although a role of SLAT in IS formation in CD8+ T cells remains to be formally demonstrated, we hypothesize that altered IS formation, most likely due to abrogated Cdc42-mediated actin accumulation at the T cell–APC interface, accounts for the impaired priming and proliferation of Def6−/− CD8+ T cells in vivo. A recent study showed that SLAT accumulates at the center of the IS, where it may contribute to the activation of Cdc42, which is colocalized at the same site (34). However, several studies ascribe to CDC42 and its effector, Wiskott–Aldrich syndrome protein, a function in later stages of CD8+ T cell differentiation; that is, in

**FIGURE 4.** SLAT is required for proliferation and IL-2–dependent survival of CD8+ T cells. WT or knockout (KO) (CD45.2+) OT-I CD8+ T cells (5 × 10^5) were labeled with CFSE and injected i.v. into naïve B6.SJL (CD45.1+) mice. One day later, the mice were immunized with 5 × 10^6 Act-mOVA/Kb splenocytes. Splenocytes were harvested 3 d later, and the proliferation of OT-I cells was analyzed by FACS analysis of CFSE dilution after gating on live CD8+ T cells. (A) Numbers in the right panels indicate the percentage of WT or KO OT-I CD8+ T cells among CD8+ splenocytes (mean ± SEM of six to seven mice). (B) Frequency of OT-I cells at each cell division cycle. *p < 0.05, **p < 0.005, ***p < 0.0005 (two-tailed unpaired t test). (C–E) CFSE-labeled purified CD8+ T cells from WT or Def6−/− (KO) mice were stimulated with plate-coated anti-CD3 (5 μg/ml) plus soluble anti-CD28 (2.5 μg/ml) mAbs for 72 h in the absence or presence of exogenous IL-2 (100 U/ml). Cells were then stained with annexin V and active caspase-3 Ab and analyzed by flow cytometry. (C) CFSE dilution and active caspase-3 staining allow concurrent assessment of cell division and cell death of CD8+ T cells. Numbers indicate the percentage of active caspase-3+ cells. (D) The percentage of active caspase-3+ CD8+ T cells with more than two divisions upon 72 h of stimulation is shown. (E) The percentage of active caspase-3+ annexin V+ CD8+ T cells at the indicated times is determined. Data are representative of four (A, B) and three (C–E) independent experiments.
the polarization of cytolytic effectors at the CTL–target cell interface, rather than in CD8+ T cell priming (35, 36). Our data suggest that SLAT functions in CD8+ T cells in a manner distinct from that of other GEFs that are known to activate Cdc42, such as DOCK8 and Vav, as these other GEFs were reported to play a key role in the persistence of CD8+ T cell memory (37) and in CTL lytic activity via regulation of cytolytic effector polarization toward target cells (38, 39). In agreement with the idea that SLAT-mediated CDC42 activation plays a role in CD8+ T cell priming, we have shown that Def6 deficiency does not impair the formation of effector KLRG1hiCD127lo (SLEC) and memory KLRG1lo CD127hi (MPEC) CTL populations in response to immunization with Lm-OV A or Actm-OV A/Kb2/splenocytes. However, the number of memory cells generated after contraction was reduced, most likely reflecting a secondary outcome of the initial expansion defect. Moreover, a more severe defect in

FIGURE 5. Constitutively active Cdc42 or NFAT1 rescue primary expansion of Def62/2 CD8+ T cells. (A) Primary WT and knockout (KO) CD8+ T cells were activated with anti-CD3 plus anti-CD28 (5 and 2.5 μg/ml, respectively) mAbs for the indicated times. Cytoplasmic (C) and nuclear (N) fractions were immunoblotted with an NFAT1-specific Ab. Fractions were also immunoblotted with α-tubulin– and lamin B–specific Abs to confirm purity of the cytosolic and nuclear fractions, respectively. (B) Experimental setup used to assess the role of SLAT-mediated NFAT1 and CDC42 activation in CD8+ T cell expansion. The top panel describes the generation of retrogenic mice, followed by sorting of retrovirally transduced (GFP+) naive WT or KO CD8+ T cells, which are used as donor cells for coadptive transfers into immunized WT recipients, as described in the bottom panel. (C and D) WT (CD45.1+) or KO (CD45.2+) BM progenitor cells from respective OT-I TCR-Tg mice were transduced either with the control empty retrovirus (WT and KO; mock) or with retroviruses encoding the constitutively active Cdc42 (KO; Cdc42CA) or NFAT1 (KO; NFAT1CAΔdimer). Transduced GFP+ BM cells were sorted and injected i.v. into sublethally irradiated Rag12/2 mice. Eight weeks later, WT or KO naive OT-I CD8+ cells (tetramer+, CD62Lhigh, and CD44low) were sorted from spleen cell suspensions. WT and KO cells (50 cells each) were transferred as indicated into recipient B6 (CD45.1/2+) mice. One day later, the recipient mice were immunized with 5 × 106 Act-mOVA/Kb2/2 splenocytes and CD8+ T cell expansion of the transferred cells was analyzed on day 7 postchallenge. The frequency of WT and KO OT-I CD8+ T cells among CD8+ T cells in the blood (mean ± SEM, n = 5). (D) Average ratio of WT/OT-I KO OT-I CD8+ T cells (n = 5). The ratio in nonimmunized animals is set at 1. Data are representative of three independent experiments. NFAT1-P, phosphorylated NFAT1; NFAT1-deP, dephosphorylated NFAT1.
CD8+ T cell expansion requires SLAT

Secondary expansion upon Ag rechallenge was observed (5- to 8-fold reduction in the numbers of Def6−/− T cells depending on the immunization model) compared with the 2- to 3-fold defect in T cell expansion after Ag priming (Supplemental Figs. 2, 3). This difference suggests an additional role of SLAT in memory T cell expansion, in addition to its crucial role in primary CD8+ T cell expansion. Supporting a role of Cdc42 in the first phase of CD8+ T cell differentiation from naive into effector cells, a gene expression profile of naive versus effector CD8+ T cells has shown that Cdc42 was upregulated in effector, but not in memory, CD8+ T cells by comparison with naive CD8+ T cells (40). However, in the case of Def6 deficiency, the cytolytic activity, degranulation, and cytokine production evaluated in equivalent numbers of CTLs from immunized mice was also not altered. Altogether, these observations suggest that SLAT, unlike other Cdc42 activators, may be part of a qualitatively unique TCR-induced signalosome or it may be involved in stage-specific signaling pathways that control CD8+ T cell expansion but not other phases of the response. Of note, these findings held true in several distinct experimental settings, which differ by the strength of the antigenic stimulation and level of inflammation; that is, the splenocyte cross-priming pathway (in the absence of overt systemic inflammation) versus the more inflammatory Lm-OVA model. Consistent with these in vivo findings, Def6−/− CD8+ T cells also showed a clear proliferative defect in response to anti-CD3/CD28-mediated costimulation in vitro independently of the concentration of the anti-CD3 Ab (Supplemental Fig. 4A). These findings suggest that SLAT is not critically involved in setting signaling thresholds, but rather it qualitatively modulates TCR signaling.

Primary CTL expansion in vivo is the result of the integration of signals originating from a variety of different signaling cascades, which imprint differentiation of clonal precursors during initial priming into various functional subsets by orchestrating gene programs governed by master transcriptional factors such as STAT1 (41) and Bcl11b (42). Our previous studies in CD4+ T cells show that SLAT is a key component of the Ca2+/NFAT signaling pathway, thereby controlling CD4+ T cell differentiation into effector Th1, Th2, or Th17 subsets (6, 10, 11, 21). Although extensively studied in the context of CD4+ T cell activation and differentiation, the role for NFAT during CD8+ T cell responses has been addressed its role in clonal expansion of CD8+ T cells. NFAT1 has been shown to partially regulate IFN-γ production by naive CD8+ T cells (13). In a model of chronic viral infection, silencing of cytokine production has been linked to a selective impairment of NFAT nuclear translocation in CD8+ T cells, whereas cell-directed effector functions, such as degranulation and cytotoxicity, remained intact (15). Finally, the calcineurin/NFAT pathway has been implicated in CD8+ T cell tolerance in vivo (14). Because SLAT controls NFAT activation in a CDC42-dependent manner in CD4+ T cells, and we showed in this study that Cdc42CA rescued the defective expansion of the Def6−/− CD8+ T cells, we propose that impaired SLAT-dependent, CDC42-mediated NFAT activation is the underlying mechanism for the impaired expansion of CD8+ T cells. Consistent with such a mechanism, our results show that NFAT1 failed to translocate to the nucleus in stimulated Def6−/− CD8+ T cells, and, second, a constitutively active form of NFAT1 bypassed Def6 and restored CD8+ T cell expansion. Thus, our findings reveal a heretofore unrecognized role for NFAT1 in CD8+ T cell biology by demonstrating for the first time to our knowledge that SLAT controls the clonal expansion of CD8+ T cells in vivo through a CDC42/NFAT signaling pathway. Our findings differ from another study (13) reporting that Nfat1−/− CD8+ T cells show a drastic impairment in IFN-γ production after in vitro anti-CD3 stimulation, which we did not observe in the Def6−/− T cells. Thus, the absence of SLAT is likely to lead to more compound alterations in signaling compared with Nfat1 deletion, as SLAT may have additional targets beyond NFAT, including some target(s) that could potentially negatively regulate IFN-γ production and antagonize positive regulation by NFAT. In this scenario, IFN-γ expression would be intact even in the absence of SLAT. Further work aimed at elucidating the molecular pathways through which SLAT links Cdc42 to NFAT activation in cycling CD8+ T cells and identifying SLAT-interacting partners in its regulatory signaling complex may unveil targets for the development of vaccination and therapeutic strategies.

Acknowledgments
We thank Yun-Cai Liu for helpful comments; Ann J. Canonigo-Balancio and Susan Togher for mouse genotyping; and Cheryl Kim, Kurt Van Gunst, and Anthony Jose for assistance with flow cytometry and cell sorting.

Disclosures
The authors have no financial conflicts of interest.

References